• Corpus ID: 8851620

Precision in Addiction Care: Does It Make a Difference?

  title={Precision in Addiction Care: Does It Make a Difference?},
  author={J. C. van der Stel},
  journal={The Yale Journal of Biology and Medicine},
  pages={415 - 422}
  • J. C. van der Stel
  • Published 24 November 2015
  • Psychology
  • The Yale Journal of Biology and Medicine
This perspective article explores the possibilities of precision in addiction care — even better individually fitted or tailor-made care — and examines what changes we need to make in order to realize sensible progress in epidemiological key figures. The first part gives a short review on the development of addiction care and tries to answer the question of where we stand now and what has been achieved in addiction science through the development and evaluation of interventions in the past… 

Pharmacogenetics of alcohol use disorder treatments: an update

This work reviews the literature on the pharmacogenetics of AUD treatment using both approved and off-label medications, highlighting valuable mechanistic insights and underscoring the potential value of precision-based care for AUD.

Innovative Treatment Approaches in Gambling Disorder

Excessive gambling behavior is a complex psychopathological phenomenon, characterized by the interaction of multiple etiological factors and by a very heterogeneous symptomatological expression. To

Applying methods for personalized medicine to the treatment of alcohol use disorder.

Personalized medicine methods, and PITE in particular, have the potential to identify individuals most likely to benefit from one versus another intervention and to provide predictions of which will work best for individuals with AUD.

Psychosocial interventions in stimulant use disorders: a systematic review and qualitative synthesis of randomized controlled trials.

All psychosocial interventions for stimulant use disorders investigated in randomized controlled trials are described - including contingency management, cognitive behavioral interventions, community reinforcement approach, 12-step program, meditation-based interventions and physical exercise - and the main findings are synthesized.

Development of an MRI-Compatible Nasal Drug Delivery Method for Probing Nicotine Addiction Dynamics

An MRI-compatible nasal delivery method enables the measurement of neural circuit responses to drug doses on a single-subject level, allowing the development of data-driven predictive models to quantify individual dysregulations of the reward control circuit causing addiction.

Development of an MRI Compatible Nasal Drug Delivery Method: Probing Nicotine Addiction Dynamics

A MR-compatible nasal delivery method enables the measurement of neural circuit responses to drug doses on a single-subject level, allowing the development of data-driven predictive models to quantify individual dysregulations of the reward control circuit causing addiction.

UvA-DARE (Digital Academic Repository) Innovative Treatment Approaches in Gambling Disorder

Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons.

PET imaging of kappa opioid receptors and receptor expression quantified in neuron-derived extracellular vesicles in socially housed female and male cynomolgus macaques

The findings suggest that the KOR is an important target for understanding the neurobiology associated with vulnerability to abused drugs and sex differences, and detectable in peripheral circulation.

REM Sleep Engages MCH Neurons to Reduce Cocaine Seeking



The Development and Maintenance of Drug Addiction

It is agreed that addiction begins with the formation of habits through positive reinforcement and that drug-opposite physiological responses often establish the conditions for negative reinforcement to come into play at a time when tolerance, in the form of increasing reward thresholds, appears to develop into positive reinforcement.

Behavioral addictions: a novel challenge for psychopharmacology

Current data on pharmacological treatment of behavioral addictions is reviewed to improve knowledge on their psychopathological, clinical, and neurobiological features and have relevant implications for more focused preventive and therapeutic strategies.

Individualized medicine – ethical, economical and historical perspectives

The volume starts with a definition of the term “Individualized Medicine” (IM) which is resilient in terms of academic science studies and focuses on the questions related to the evaluation of health economics: IM has the potential to alter the rules, institutions and regulations of the health care sector.

The Neurobiology of Addiction: Where We Have Been and Where We Are Going

The major developments in the understanding of the molecular biology of the endogenous opioid system and the use of genomics to advance the knowledge of the function and regulation of opioid receptors and endorphins are reviewed.

Defining substance use disorders: do we really need more than heavy use?

'Heavy substance use over time' seems to be a definition of substance use disorders in line with results of basic research and epidemiology and reduces stigmatization.

Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature

  • Shih-ku Lin
  • Psychology, Biology
    British journal of clinical pharmacology
  • 2014
Specific compounds were selected that are known to diminish desire to use (anticraving effect) and that have been trialled for a number of different substance addictive disorders and their therapeutic potential in clinical practice is discussed in light of their efficacy.

People with alcohol use disorders in specialized care in eight different European countries.

High levels of consumption, somatic and mental comorbidities, disability and functional losses were found in this representative treatment sample, indicating that treatment was initiated only at severe stages of AUDs.

Evidence-based pharmacological treatment of substance use disorders and pathological gambling.

It is concluded that great progress has been made in the last three decades and that currently evidence-based pharmacological treatments are available for smoking cessation, alcohol and opioid dependence and pathological gambling.